Skip to main content
SpringerLink
Log in

Hormonal Regulation of Transforming Growth Factor-β in Breast Cancer

  • Chapter
Transforming Growth Factor-β in Cancer Therapy, Volume II

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1551 Accesses

Abstract

Antihormones which are commonly used in breast cancer therapy block the stimulating effects of estrogens by activating inhibitory factors like transforming growth factor-β (TGF-β). Activation of TGF-β isoforms and TGF-β signal transduction pathways by antihormones has been studied in detail in vitro in breast cancer cell lines and demonstrated in vivo in samples from breast cancer patients receiving tamoxifen therapy. Regulation of TGF-β is not restricted to antiestrogens. Other hormonal substances like progestins and retinoids induce comparable effects.

TGF-β is a potent inhibitor of most human breast cancer cells however it also influences angiogenesis and extracellular matrix deposition and can suppress the immune system. Thus, a failure of TGF-β inhibitory loops might contribute to the development of resistance against antiestrogen treatment in later tumor stages.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Siegal R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. Russo IH, Russo J Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasial 1998;3:49–61.

    Article  CAS  Google Scholar 

  3. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev 1995;16:559–589.

    CAS  PubMed  Google Scholar 

  4. Cianfrocca M, Gradishar WJ. Controversies in the therapy of early stage breast cancer. Oncologist 2005;10:766–779.

    Article  CAS  PubMed  Google Scholar 

  5. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48:417–428.

    Article  CAS  PubMed  Google Scholar 

  6. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937s–943s.

    CAS  PubMed  Google Scholar 

  7. Jeng MH, ten DP, Iwata KK, Jordan VC. Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects, on the proliferation of human breast cancer cells. Mol Cell Endocrinol 1993;97:115–123.

    Article  CAS  PubMed  Google Scholar 

  8. Knabbe C, Kopp A, Hilgers W, et al. Regulation and role of TGF beta production in breast cancer. Ann. N Y Acad Sci 1996;784:263–276.

    Article  CAS  Google Scholar 

  9. Harpel JG, Schultz-Cherry S, Murphy-Ullrich JE, Rifkin DB. Tamoxifen and estrogen effects on TGF-beta formation: role, of thrombospondin-1, alphavbeta3, and integrin-associated protein. Biochem Biophys Res Commun 2001;284:11–14.

    Article  CAS  PubMed  Google Scholar 

  10. Buck M, von der FJ, Knabbe C. Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann N Y Acad Sci 2002;963:140–143.

    Article  CAS  PubMed  Google Scholar 

  11. Arrick BA, Korc M, Derynck R. Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res 1990;50:299–303.

    CAS  PubMed  Google Scholar 

  12. Buck MB, Pfizenmaier K, Knabbe C. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol 2004;18:1643–1657.

    Article  CAS  PubMed  Google Scholar 

  13. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 Suppl 1991;2:S15–S20.

    Google Scholar 

  14. Muller V, Jensen EV, Knabbe C. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res 1998;58:263–267.

    CAS  PubMed  Google Scholar 

  15. Feng XH, Derynck R. Specificity and versatility in TGF-signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659–693.

    Article  CAS  PubMed  Google Scholar 

  16. Benson JR, Wakefield LM, Baum M, Colletta AA. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br J Cancer 1996;74:352–358.

    CAS  PubMed  Google Scholar 

  17. Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990;62:405–409.

    CAS  PubMed  Google Scholar 

  18. MacCallum J, Keen JC, Bartlett JM, Thompson AM, Dixon JM, Miller WR. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer 1996;74:474–478.

    CAS  PubMed  Google Scholar 

  19. Brandt S, Kopp A, Grage B, Knabbe C. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Anticancer Res 2003;23:223–229.

    CAS  PubMed  Google Scholar 

  20. Kopp A, Jonat W, Schmahl M, Knabbe C. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 1995;55:4512–4515.

    CAS  PubMed  Google Scholar 

  21. Morena AM, Oshima CT, Gebrim LH, et al. Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-betal) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma. Neoplasma 2004;51:481–486.

    CAS  PubMed  Google Scholar 

  22. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261–4264.

    CAS  PubMed  Google Scholar 

  23. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest 1991;87:277–283.

    Article  CAS  PubMed  Google Scholar 

  24. Kalkhoven E, Kwakkenbos-Isbrucker L, Mummery CL, et al. The role of TGF-beta production in growth inhibition of breast-tumor cells by progestins. Int J Cancer 1995;61:80–86.

    Article  CAS  PubMed  Google Scholar 

  25. Kalkhoven E, Beraldi E, Panno ML, De Winter JP, Thijssen JH, van der BB. Growth inhibition by antiestrogens and progestins in TGF-beta-resistant and-sensitive breast-tumor cells. Int J Cancer 1996;65:682–687.

    Article  CAS  PubMed  Google Scholar 

  26. Dannecker C, Possinger K, Classen S. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D. Ann Oncol 1996;7:391–395.

    CAS  PubMed  Google Scholar 

  27. Herbert BS, Sanders BG, Kline K. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells. Nutr Cancer 1999;34:121–132.

    Article  CAS  PubMed  Google Scholar 

  28. Yang L, Ostrowski J, Reczek P, Brown P. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene 2001;20:8025–8035.

    Article  CAS  PubMed  Google Scholar 

  29. Normanno N, Di MM, De ME, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12:721–747.

    Article  CAS  PubMed  Google Scholar 

  30. Basolo F, Fiore L, Ciardiello F, et al. Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int J Cancer 1994;56:736–742.

    Article  CAS  PubMed  Google Scholar 

  31. Zugmaier G, Ennis BW, Deschauer B, et al. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 1989;141:353–361.

    Article  CAS  PubMed  Google Scholar 

  32. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949–6952.

    CAS  PubMed  Google Scholar 

  33. McEarchern JA, Kobie JJ, Mack V, et al. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 2001;91:76–82.

    Article  CAS  PubMed  Google Scholar 

  34. Thompson AM, Kerr DJ, Steel CM. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 1991;63:609–614.

    CAS  PubMed  Google Scholar 

  35. Buck MB, Fritz P, Dippon J, Zugmaier G, knabbe C. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004;10:491–498.

    Article  CAS  PubMed  Google Scholar 

  36. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001;276:42,908–42,914.

    Article  CAS  PubMed  Google Scholar 

  37. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137–144.

    Article  CAS  PubMed  Google Scholar 

  38. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702–2708.

    CAS  PubMed  Google Scholar 

  39. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220–1226.

    Article  CAS  PubMed  Google Scholar 

  40. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118–121.

    CAS  PubMed  Google Scholar 

  41. Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 2004;279:24,505–24,513.

    Article  CAS  PubMed  Google Scholar 

  42. Seton-Rogers SE, Lu Y, Hines LM, et al. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 2004;101:1257–1262.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

    Miriam Buck PhD

  2. Department of Laboratory Medicine, Robert Bosch Hospital, Stuttgart, Germany

    Cornelius Knabbe MD, PhD

Authors
  1. Miriam Buck PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelius Knabbe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Training Branch, Office of Centers, Training and Resources, National Cancer Institute, Bethesda, MD

    Sonia B. Jakowlew PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Buck, M., Knabbe, C. (2008). Hormonal Regulation of Transforming Growth Factor-β in Breast Cancer. In: Jakowlew, S.B. (eds) Transforming Growth Factor-β in Cancer Therapy, Volume II. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-293-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-293-9_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-715-0

  • Online ISBN: 978-1-59745-293-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation